LONDON--(MARKET WIRE)--Jul 10, 2007 -- TheraGenetics Ltd, an emerging personalised medicine diagnostics company focused on central nervous system (CNS) disorders, today announced the successful completion of a $6 million (£3 million) Series A venture financing round. Swarraton Partners led the financing with participation from Tudor Capital, IP Venture Fund, IP Group plc’s venture capital fund which was raised in partnership with the European Investment Fund, and existing investor IP Group plc. As part of the transaction, Mr. Stephen Brooke, Managing Partner of Swarraton Partners, has joined TheraGenetics’ Board of Directors.
